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Depression is a common, under-recognized, and under-
treated problem that is independently associated with
increased morbidity and mortality in CKD patients. However,
only a minority of CKD patients with depression are treated
with antidepressant medications or nonpharmacologic
therapy. Reasons for low treatment rates include a lack of
properly controlled trials that support or refute efficacy and
safety of various treatment regimens in CKD patients. The
aim of this manuscript is to provide a comprehensive review
of studies exploring depression treatment options in CKD.
Observational studies as well as small trials suggest that
certain serotonin-selective reuptake inhibitors may be safe to
use in patients with advanced CKD and ESRD. These studies
were limited by small sample sizes, lack of placebo control,
and lack of formal assessment for depression diagnosis.
Nonpharmacologic treatments were explored in selected
ESRD samples. The most promising data were reported for
frequent hemodialysis and cognitive behavioral therapy.
Alternative proposed therapies include exercise training
regimens, treatment of anxiety, and music therapy. Given the
association of depression with cardiovascular events and
mortality, and the excessive rates of cardiovascular death in
CKD, it becomes imperative to not only investigate whether
treatment of depression is efficacious, but also whether it
would result in a reduction in morbidity and mortality in this
patient population.
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Major depressive disorder, defined as a clinical syndrome
lasting for 2 weeks during which time the patient experiences
either depressed mood or anhedonia plus at least 5 of the 9
Diagnostic and Statistical Manual of Mental Disorders IV
(DSM IV) criterion symptom domains,1,2 is very common
among patients with chronic kidney disease (CKD) and end-
stage renal disease (ESRD) and is associated with adverse
outcomes.3–9 Whereas depression point prevalence is 2–10%
in the general population,10 20% of CKD patients suffer from
a major depressive episode,11,12 a prevalence even higher than
reported for other chronic diseases such as diabetes mellitus
and congestive heart failure.13,14 Depression results in
substantial functional impairment and decreased quality of
life in ESRD patients,15–17 and levels of depression and
functional and occupational impairment do not remit
spontaneously in untreated depressed patients.18 We showed
that ESRD patients on chronic hemodialysis (HD) with
depression are twice as likely to die or require hospitalization
within a year as compared with those without depression,4
and are at risk for a 30% increase in both cumulative hospital
days and number of hospitalizations.5 In a recent prospective
observational cohort study of consecutively recruited stage
2–5 CKD predialysis patients, a diagnosis of current major
depressive episode at baseline was associated with an
increased risk of a composite of death, hospitalization, or
progression to dialysis, independent of comorbidities and
kidney disease severity (adjusted hazard ratio 1.86, 95%
confidence interval 1.23, 2.84).9 Despite the high prevalence
of depressive symptoms as well as depressive disorder among
patients with CKD and ESRD and its association with poor
outcomes, only a minority of chronic dialysis patients receive
adequate diagnosis and treatment for depression.3,12,19 For
example, in a retrospective analysis of the African American
Study of Kidney Disease and Hypertension Cohort Study,
Fischer et al.20 reported that only 20% of CKD participants
with a Beck Depression Inventory (BDI) score of414 (above
the threshold validated for depression) were prescribed
antidepressant medications. Similarly, Watnick et al.12 re-
ported that only 16% of ESRD patients initiating chronic HD
with BDI scores of X15 were on antidepressants. In a
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prospective observational cohort of 98 prevalent HD patients,
nephrologists were informed about a current diagnosis of
depressive disorder based on DSM IV diagnostic criteria in
26% of cases.4 However, intervention was made in only 23%
of these patients, defined as referral to mental health clinic,
initiation of an antidepressant medication, or increasing the
dose of previously prescribed antidepressant. Thus, a major
challenge for clinicians is to develop strategies to better
understand and manage depression in CKD patients.
However, there are limited data on safety and efficacy of
antidepressant medications in patients with advanced CKD
and ESRD. In addition, instituting effective treatment
programs for depression in this patient population is
challenging.20 Recently, attention has begun to be focused
on a variety of treatment strategies that may show future
promise in selected groups of patients. The purpose of the
present manuscript is to review the available evidence on
treatment of depression in CKD patients.
SCREENING FOR AND DIAGNOSIS OF DEPRESSION
Given the high prevalence of depression in CKD patients and
the association of depression with poor outcomes and reduced
health-related quality of life, it is suggested that depression
screening be integrated into routine patient care. Screening can
take place on initial presentation of CKD patients for
evaluation in clinic, at dialysis initiation for ESRD patients,
and perhaps 6 months after initiation, and yearly thereafter.3
Several studies validated commonly used depression screening
self-report questionnaires against DSM IV-based structured
interviews among patients with CKD and ESRD.3,11,21,22
Table 1 lists the screening characteristics of these question-
naires, which can generally be completed in a few minutes.
Any of these validated scales can be used to screen patients in
CKD clinic or dialysis facilities. As seen here, the cutoff scores
with the best diagnostic accuracy for depressive disorder in
patients with predialysis stage 2–5 CKD were similar to cutoffs
used in the general population (Table 1).
However, the cutoffs for those with ESRD were generally
higher, perhaps because of more frequent presence of somatic
symptoms in ESRD that may not be manifest in earlier CKD
stages.11 Thus, somatic symptoms, such as fatigue, loss of
energy, decreased appetite, sleep disturbance, and difficulty
concentrating, suggestive of depressive affect, may be more
commonly reported by ESRD patients.19,23–25 However, for a
definitive diagnosis of depressive disorder based on DSM IV,
either feelings of sadness (depressed mood) or loss of interest
(anhedonia) must accompany these symptoms.2 If sadness or
anhedonia is absent, consideration should be given to other
causes such as dialysis inadequacy, poor nutritional status,
cognitive dysfunction, dementia, and/or exacerbation of
other comorbid illnesses, such as congestive heart failure
(Figure 1). To help distinguish these symptoms, a structured
interview should be performed to confirm a depressive
disorder in patients who screen positive before treatment is
considered. This can be performed by any of several
individuals working in the clinic or dialysis facility (ne-
phrologists or trained social workers and/or nurses).
Alternatively, referrals can be made to mental health
professionals, if clinically indicated; but this approach may
present logistical problems in terms of reimbursement issues
and referral channels. Reasons to prompt referral to mental
health include complicated depression such as with psycho-
sis, clinical suspicion for other psychiatric diseases such as
bipolar disorder, suicidal ideation, or treatment-resistant
depression (Figure 1).
Paying attention to the presence of acute suicidal intent in
depressed patients is particularly important in order to rule
out immediate threat to themselves or others, and needs to be
integrated into the patient evaluation.
TREATMENT ALGORITHMS
Once the diagnosis of clinical depression is made, treatment
options need to be tailored to the individual needs of the
patient and the resources available to the clinical team or
dialysis facility (Figure 1). Thus, the care of each patient
needs to be individually assessed and a treatment plan
developed. There are a variety of treatment options available
(discussed below), but few studies guide us as to the best
evidence-based approach. In the following section, we review
the pharmacologic and nonpharmacologic approaches to
treating depression that have been suggested and studied in
this patient population.
Pharmacologic intervention
Patients with moderate to advanced CKD and ESRD have
generally been excluded from large antidepressant trials
because of concerns for adverse events and the paucity of data
on safety of antidepressants in this population.26 This likely
has contributed to the undertreatment and underdosing of
antidepressant medications in CKD patients. In fact, few
studies have critically examined the pharmacologic treatment
of depression in CKD patients.
Table 1 | Screening characteristics of self-report depression scales in CKD and ESRD
Scale
No. of
items
Score,
range
Cutoff score in general
population
Cutoff score in CKD (sensitivity,
specificity)
Cutoff score in ESRD (sensitivity,
specificity)
BDI3,11,21,22 21 0–63 X10 X11 (89%, 88%) X14–16 (62–91%, 81–86%)
QIDS-SR11 16 0–27 X10 X10 (91%, 88%)
CESD3 20 0–60 X16 X18 (69%, 83%)
PHQ21 9 0–27 X10 X10 (92%, 92%)
Abbreviations: BDI, Beck Depression Inventory; CESD, Center for Epidemiologic Studies Depression Scale; CKD, chronic kidney disease; ESRD, end-stage renal disease;
PHQ, Patient Health Questionnaire; QIDS-SR, 16-Item Quick Inventory of Depressive Symptomatology Self-Report.
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Antidepressant medications are generally highly protein
bound and not removed significantly by the dialysis
procedure.27,28 They commonly undergo hepatic metabolism,
but many have active metabolites that are renally excreted,
leading to accumulation of potentially toxic metabolites in
patients with decreased glomerular filtration rates.27,28 In
addition, there is the risk of drug–drug interactions in CKD
and ESRD patients who, because of a large burden of
comorbidities and metabolic derangements, are already on
many medications. Several classes of antidepressants such as
serotonin modulators, tricyclics, and tetracyclics have cardiac
side effects such as QTc prolongation, arrhythmias, and
orthostatic hypotension (Table 2). Given that a large
proportion of patients with CKD and ESRD suffer from
cardiovascular (CV) disease, use of such medications without
clinical trials to advocate safety must be carefully considered.
Central nervous system depression is also a common adverse
event. Increased bleeding risk was reported in association
with serotonin-selective reuptake inhibitors (SSRIs),29 which
may become problematic in advanced CKD and underlying
platelet dysfunction related to uremia. Finally, the serotoner-
gic gastrointestinal activity of SSRIs, one of the most
commonly used antidepressant classes, can result in nausea
and vomiting, which again may exacerbate these symptoms
in patients with predialysis stage 5 CKD and ESRD.27,30
There are insufficient data to clearly suggest that treatment
of major depressive disorder is either efficacious or changes
outcomes in advanced CKD and ESRD patients.3,31,32 Few
studies have examined this issue and are fraught with serious
limitations including small sample sizes,33–37 lack of placebo
control,32–35,37,38 and lack of DSM IV-based criteria for major
depressive disorder.35,36,38 Nonrandomized observational
studies of antidepressant medications in ESRD patients on
chronic peritoneal dialysis reported some improvement in
depressive symptoms;32,33 however, major limitations in-
cluded the lack of a control group, selection and refusal bias,
and a 50% medication discontinuation rate. A total of 136
patients with ESRD on chronic peritoneal dialysis who scored
X11 on the BDI depression questionnaire were studied.32,33
Only 51% agreed to be further evaluated, and of those, only
72% agreed to have pharmacologic treatment. Finally, merely
23 of 44 (52%) of patients who agreed with treatment
completed a 12-week course of antidepressant medications.
Although a mean decrease in BDI scores from 17.1±6.9 to
8.6±3.2 was reported in completers, this study does
underline the fact that even when ESRD patients were given
a diagnosis of depression and treatment recommended, not
all agreed to medical management.32,33
In another study, Atalay et al.39 reported that treatment with
SSRI sertraline at 50mg per day for 12 weeks was associated
with a decrease in depressive symptoms in 25 chronic peritoneal
dialysis patients, with BDI scores decreasing from 22.4 to 15.7
(Po0.001). Lack of a control group and small sample size were
major limitations. In addition, mean posttreatment BDI score
was still above the cutoff for depression. Koo et al.37 reported
treatment of 34 dialysis patients with another SSRI, paroxetine,
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Figure 1 |Proposed algorithm for management of depression in patients with CKD and ESRD. Alternative therapies include
psychotherapy, counseling, social support, and music therapy. CKD, chronic kidney disease; ESRD, end-stage renal disease; MDE, major
depressive episode.
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Table 2 | Antidepressant medication classes and dosing in CKD
Medication class and dosing in normal eGFR Dosing in CKD and ESRD Potential class adverse effects32
Selective serotonin reuptake inhibitors
Sertraline 50–200mg/day, single dose No dose adjustment recommended, but active
metabolite is renally excreted
Increased risk of bleeding; GI
symptoms including nausea and
diarrhea; CNS effects; sexual
dysfunction; hyponatremia
Paroxetine
Immediate-release 20–50mg/day, single dose
Controlled-release 25–62.5mg/day, single dose
Elimination half-life prolonged if CrClo30ml/min
Immediate-release: 10mg/day initial dose, max
40mg/day
Controlled-release: 12.5mg/day initial dose, max
50mg/day
Fluoxetine 20–80mg/day, single dose No dose adjustment recommended, but long
half-life; use with caution
Citalopram 20–40mg/day, single dose Initial dose 10mg/day; active metabolite.
Not recommended for eGFR o20ml/min
Higher citalopram doses associated
with QTc prolongation, torsades de
pointes
Escitalopram 10–20mg/day, single dose Use with caution in severe renal impairment
Dopamine/norepinephrine reuptake inhibitors
Bupropion 200mg/day, 2 divided doses
Max 450mg/day, 3–4 divided doses
Active metabolite; reduce frequency and/or dose Accumulation of toxic metabolites;
cardiac dysrhythmia; wide QRS
complex; nausea, insomnia,
dizziness
Noradrenergic and serotonergic agonist
Mirtazapine 15–45mg/day at bedtime Reduce dose; clearance reduced by 30% if CrCl
11–39ml/min, and by 50% if CrCl o10
CNS effects including somnolence;
weight gain
Tricyclics and tetracyclics (TCAs)
Amitriptyline 75–150mg/day, 1–3 divided doses Generally avoid TCAs given cardiac side effects
No dosage adjustment recommended
QTc prolongation, arrhythmias,
orthostatic hypotension; CNS and
anticholinergic effects
Desipramine 100–300mg/day, singly or divided Caution advised if eGFR o15ml/min; avoid given
cardiac side effects
Doxepin 25–300mg/day, singly or divided No dosage adjustment recommended
Nortriptyline 25mg/day, 3 to 4 times daily
Max 150mg/day
No dosage adjustment recommended
Serotonin/norepinephrine reuptake inhibitors
Venlafaxine
Immediate-release 75–225mg/day, 2–3 divided
Extended-release 37.5–225mg/day, singly
Reduce dose by 25 to 50% in patients with mild-
to-moderate renal impairment
Hypertension, sexual dysfunction,
neuroleptic malignant syndrome,
serotonin syndrome, accumulation
of toxic metabolite O-
desmethylvenlafaxine
Serotonin modulators
Nefazodone 100–600mg/day, 2 divided doses Generally avoid in cardiovascular or liver disease
Increase dose carefully
Cardiac dysrhythmias,
Stevens–Johnson syndrome, liver
failure, serotonin syndrome,
priapism
Trazodone
Immediate-release 150–400mg/day, divided
Extended-release 150–375mg/day, singly at night
Increase dose carefully; use divided doses in
elderly
Monoamine oxidase inhibitors (MAOIs)
Phenelzine 45–90mg/day, 3 divided doses Avoid MAOI in CKD because of drug–drug
interactions, although no dose adjustment
advised for mild-to-moderate renal impairment
Significant drug–drug interactions;
risk of hypertensive crisis with
tyramine-rich foods; orthostatic
hypotension
Selegiline transdermal patch, 6mg per 24 h,
may increase every 2 weeks by 3mg per 24 h
up to 12mg per 24 h
Abbreviations: CKD, chronic kidney disease; CNS, central nervous system; CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease;
GI, gastrointestinal.
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder and other
psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults beyond age 24 years, and
there was a reduction in risk with antidepressants compared with placebo in adults aged X65 years.27
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at 10mg per day for 8 weeks concurrently with psychotherapy.
Although the authors reported a statistically significant decrease
in Hamilton Depression Rating Scale scores (from 16.6±7.0
to 15.1±6.6, Po0.01), the clinical relevance of 1.5 unit decrease
in score is unclear. This study also suffered from the lack of
a placebo-control group and short-term follow-up. Finally,
a randomized double-blinded placebo-controlled trial of
fluoxetine treatment in 14 chronic HD patients with major
depression revealed a statistically significant improvement in
depression at 4 weeks that was not sustained at 8 weeks.36
No patients discontinued study drug because of adverse events,
all of which were reported as minor. Furthermore, all patients
in the intervention arm had serum plasma concentrations of
fluoxetine and norfluoxetineo250ng/ml at 8 weeks, similar to
reported levels in patients with normal renal function. Although
this study suggests promise for use of SSRIs in HD patients, the
short duration and small sample size did not allow for adequate
assessment of adverse effects.
Given the lack of data in CKD and ESRD patients, one
might reflect on the antidepressant medication data that do
exist in non-CKD patients, particularly those with CV
disease. The association of depression with increased
morbidity and mortality was also reported in non-kidney
disease patients, especially in patients with CV disease.40,41
The Sertraline AntiDepressant Heart Attack Randomized
Trial (SADHART), a randomized, double-blinded placebo
controlled trial, was conducted to assess the safety and
efficacy of SSRI sertraline treatment in 369 patients with
major depressive disorder after acute coronary syndrome.26
This trial documented efficacy and no evidence of CV harm
for sertraline treatment initiated for an average of 34 days
after acute coronary syndrome.26 Importantly, there were
20% fewer serious adverse CV events in the sertraline-treated
group versus the placebo group, although this trend did not
reach statistical significance.26 However, this study was not
powered to assess CVevents, and to confirm a 20% reduction
in CV risk, a sample size of 4000 would have been required.
Unfortunately, patients with stage 3b–5 CKD and ESRD,
which are precisely the groups at highest risk for CV
morbidity and mortality, were excluded from SADHART
because of safety concerns. The discouraging lack of data calls
for large randomized placebo-controlled trials where CKD
subjects are consecutively recruited and outcomes are blindly
assessed. The Chronic Kidney Disease Antidepressant Sertra-
line Trial (CAST study) (http://www.clinicaltrials.gov, clinical
trials identifier number NCT00946998) is a double-blinded
placebo-controlled trial presently recruiting participants to
investigate whether treatment of a current major depressive
episode with sertraline versus placebo improves depression
severity and overall function and quality of life in patients
with stage 3–5 predialysis CKD. Secondary outcomes include
safety and tolerability.
Recommendations
Until more data are available for treatment of depression in
CKD, nephrologists are left with the conundrum of adding
another medication to the growing list prescribed to patients
with advanced CKD or ESRD, considering nonpharmacolo-
gic therapy, or worse yet, dismissing depressive symptoms as
nonspecific symptoms of chronic disease or uremia. How-
ever, data clearly suggest that both depression diagnosis and
depressive symptoms independently prognosticate poor out-
comes in these patients. Therefore, such symptoms should
not be ignored.
Based on what data are available, if a trial of medication is
considered, SSRIs would likely be a prudent choice because of
established safety in patients with CV disease (Table 2).
Table 2 lists the most common classes of antidepressant
medications with specific drug examples, suggested dosing in
renal impairment, and potential adverse effects. Once
medication is initiated, response to treatment, need for dose
adjustment, and the development of side effects should be
monitored closely. This can be easily accomplished in ESRD
patients given repeated encounters with health-care providers
during routine presentation to the HD unit. The medication
dose should not be escalated sooner than at intervals of at
least 1 to 2 weeks, and only as tolerated. Special attention
should be given to drug–drug interactions, as well as
increased risk of suicidal ideation after initiation of
antidepressant medications.
NONPHARMACOLOGIC INTERVENTIONS
Given the concerns and potential problems with pharmacologic
treatment of depression in patients with advanced CKD and
ESRD, potential nonpharmacologic interventions have been
considered (Figure 1). These approaches, however, are likely to
challenge health-care providers given the organization and
structure of CKD and ESRD care in most countries (that is, the
limited resources available for and limited recognition of the
significance of providing psychosocial support). Importantly,
several studies have now suggested an improvement in
depressive symptoms in ESRD patients treated with various
nonpharmacologic regimens, including alterations in the
dialysis treatment regimen,42,43 exercise therapy,44,45 and
cognitive behavioral therapy.46 In addition, consideration needs
to be given to alternative approaches that have been used to
treat depressed patients in the general population but which
have not been systematically studied in CKD patients.47–49
Alterations in the dialysis treatment
Two recent trials have focused attention on the impact of
alterations in the dialysis treatment regimen on depressive
symptoms in HD patients.42,43 These studies lend support to
previous work that observed a beneficial impact of more
frequent HD on various health-related quality-of-life mea-
sures.50–52 First, the FREEDOM (Following Rehabilitation,
Economics and Everyday-Dialysis Outcome Measurements)
study is an observational cohort study of patients changing to
six times per week HD with the NxStage machine with
targeted standardized weekly KT/V of a minimum of 2.1.53
In all, 239 participants were enrolled (intention-to-treat
cohort), but only 128 completed the study (per-protocol
Kidney International (2012) 81, 247–255 251
SS Hedayati et al.: Management of depression in CKD rev iew
cohort). After conversion to six times per week HD, BDI
scores decreased from baseline values of 11.2±0.8 to
7.4±0.6 at 4 months, and this improvement was sustained
at 12 months (7.8±0.7; Po0.001), in the per-protocol
analysis.42 The greatest improvement in depressive symptoms
was noted in those with the highest baseline BDI scores, and
those with scoresX16 had a decrease in scores from 25±1 to
14.1±0.9 (Po0.001).42 However, the intention-to-treat
analysis revealed less robust results, and BDI scores decreased
from 12.8 to 10.7 (Po0.001). One criticism of this study was
that percent prescribed antidepressant and anxiolytic med-
ications also increased during the course of the study from 26
to 35% (P¼ 0.02). However, after adjustment for antide-
pressant use, the improvement in BDI scores remained
statistically significant. Given the lack of a control group, the
improvement in BDI scores may have occurred for reasons
other than the intervention alone.
The Frequent Hemodialysis Network (FHN) is a 12-
month randomized trial comparing six times per week
in-center HD with three times per week conventional HD.43
Standardized KT/Vs in the former group were 3.54±0.56
compared with 2.49±0.27 in the latter group. Significant
improvements in the physical health composite score of
the Short Form-36 (SF-36) health-related quality-of-life
questionnaire were observed. BDI scores were lower in the
six times per week HD patients, but the difference was not
statistically significant.43
Cognitive behavioral therapy
Cognitive behavioral therapy (CBT) is a well-documented
treatment option for patients with various psychiatric
disorders.54 It is based on the premise that poor decisions,
ineffective problem solving, and distorted or emotional
thinking can result from ‘automatic thoughts’ in response to
strong negative feelings and/or emotions. CBT uses well-
structured techniques to support logical thinking and
reorganize negative thoughts, behavior adjustments, and
consequently mood status. In a recent 9-month randomized
trial of CBT in Brazil, 85 HD patients with a major depressive
disorder on standardized interviewing were randomized to
receive standard care (control group) or CBT with a trained
psychologist.46 Group sessions were held weekly for 12 weeks,
and then monthly maintenance sessions were continued.46
Baseline BDI scores decreased from B25 in both groups to
10.8±8.8 in the treatment group versus 17.6±11.2 in the
control group (between-group comparison Po0.002) at 9
months. These significant improvements in depressive symp-
toms in the treatment group were confirmed with standar-
dized patient interviews. Several domains on the KDQOL-SF
(Kidney Disease Quality of Life questionnaire-Short Form)
improved as well.
The benefit of CBT on a broader scale was observed in an
interesting study of 69 ESRD patients in 22 dialysis units in
Louisiana after hurricane-related trauma.55 Social workers
were provided with training kits from the National Kidney
Foundation using a cognitive behavioral framework. There
was a significant amelioration of depressive symptoms in
patients who participated in sessions as compared with
patients who did not discuss the material with their social
worker. Importantly, this study involved 22 social workers
with limited but focused training, suggesting that more
widespread use of CBT techniques may be promising in
ESRD facilities and/or CKD clinics.56
The possible efficacy of combining antidepressant medica-
tions with CBT in CKD patients has not been explored in
published studies.57 This is relevant as a large recent study
involving 681 patients with chronic major depression showed
that the response rate to medication or CBT alone was 48%,
compared with a 73% response rate in patients receiving
combined therapy.57 It would seem reasonable to explore
trials involving combined approaches given the challenges
presented in treating the CKD patient with depression.
Exercise training programs
The impaired physical functioning of ESRD patients is well
documented, the causes of which are multifactorial.58 An
association between physical functioning impairments and
various health-related quality-of-life measures has been well
established.59 Thus, recent studies suggesting a beneficial effect
of exercise programs on depressive symptoms in ESRD are
of interest.44,45 A randomized 2 2 factorial trial of anabolic
steroid administration and resistance exercise training was
conducted in 79 maintenance HD patients.60 Interventions
included double-blinded weekly nandrolone decanoate or
placebo injections and lower extremity resistance exercise
training for 12 weeks during HD using ankle weights. Exercise
was associated with an improvement in self-reported physical
functioning on the Physical Functioning scale of the SF-36
(P¼ 0.03). In addition, there was a trend toward a reduction in
fatigue in the groups that were assigned to exercise (P¼ 0.06).
In another trial of HD patients with reduced aerobic capacity
(measured as VO2 max (volume per time, oxygen, maxi-
mum)), 35 patients were randomized to a 10-month
intradialytic exercise training program.44 There was a 21%
increase in VO2 max in the exercise group and a 39% reduction
in BDI scores—significantly different than in the control
group, in whom there was no change in either exercise capacity
or BDI scores.44 Finally, BDI scores decreased by 34.5%
(Po0.001) in 24 HD patients randomized to a 1-year
intradialytic exercise training program versus 20 patients
randomized to control group.61 There was an inverse
correlation between BDI scores and heart rate variability
indices before and after exercise training, suggesting that
decreased heart rate variability may play a mechanistic role in
the association of depression with poor CV outcomes.
OTHER POTENTIAL APPROACHES AND FUTURE DIRECTIONS
Among symptoms in ESRD patients, pain, sexual dysfunc-
tion, and anxiety are commonly encountered. A total of 44%
of prevalent chronic HD patients were observed to have an
anxiety disorder, and in 33% of those, the anxiety disorder
persisted at 16 months.62 A strong association between
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anxiety and depressive symptoms was noted.62 Given this
association, could the treatment of anxiety improve depres-
sive symptoms in selected patients? The SMILE study
(Symptom Management Involving End-Stage Renal Disease)
is a multicenter, randomized trial comparing the effectiveness
of two strategies (provider based vs. management inter-
vention based) for treatment of symptoms in chronic HD
patients.63 The primary outcome includes changes in scores
on pain, erectile dysfunction, and depression scales.
Alternative interventions to treat depression in ESRD patients
include addressing marital and family discord and barriers to
social interactions. Marital and family tensions in ESRD patients
are well documented, related at least in part to the stress of
illness.64,55 These tensions have been associated with the presence
of a depressive affect.64 Problems with social interactions of
ESRD patients are also well documented and have been
associated with poor outcomes.65 Involvement of community
and religious organizations could be explored.65–67 Addressing
the concerns of caregivers of patients with disabilities may also
be helpful in relieving stress in difficult relationships.68
Other approaches used in non-ESRD samples to treat
depression can be considered. A recent Cochrane analysis
suggested that music therapy can have a beneficial impact on
depressive symptoms.47 Importantly, patient acceptance of
the therapy was high and dropout was low in all five studies
critically examined. Furthermore, music therapy was shown
to be beneficial in patients with a variety of chronic,
advanced illnesses.48 Music and art therapy can take
advantage, perhaps, of the length of time dialysis patients
stay idle during the dialysis treatment.
Future directions could include exploring the possible
association of depression with inflammation in CKD
patients. Data suggest that the reduction in cytokine
activation associated with inflammatory conditions alone
without the concomitant administration of antidepressant
medications can result in amelioration of depressive
symptoms. For example, in 618 patients with psoriatic
arthritis treated with etanercept, there was marked improve-
ment in depressive symptoms, independent of an improve-
ment in associated skin or joint problems.69
CONCLUSIONS
Patients with CKD suffer from a disproportionate burden of
CV morbidity and mortality both before and after chronic
dialysis initiation. However, interventions aimed at modify-
ing risk factors associated with poor outcomes in these
patients have not always translated into improved out-
comes.70–73 In fact, some interventions, such as the use of
erythropoiesis-stimulating agents in the TREAT trial, were
associated with harm.73 Yet, as nephrologists, we spend hours
during dialysis rounds in an attempt to fine-tune measures of
anemia, dialysis adequacy, mineral metabolism, and dyslipi-
demia. Depression has now become a public health priority,
and the US Preventive Services Task Force recommends
screening for depression if systems are in place to assure
accurate diagnosis and effective treatment.9,74 It, therefore,
becomes important to institute strategies to screen for and
diagnose depression in CKD patients. What needs to be
determined is whether or not treatments are efficacious and
safe in this patient population, and then effective treatment
algorithms need to be implemented. Importantly, the impact
of treating depression on morbidity and mortality needs to
be established. But, it must be emphasized that the successful
amelioration of clinical depression and its symptoms may in
and of itself be a valid therapeutic goal.
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